R
Richard B. Kim
Researcher at University of Western Ontario
Publications - 380
Citations - 33088
Richard B. Kim is an academic researcher from University of Western Ontario. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 89, co-authored 328 publications receiving 30436 citations. Previous affiliations of Richard B. Kim include London Health Sciences Centre & St. Jude Children's Research Hospital.
Papers
More filters
Journal ArticleDOI
Identification of single nucleotide polymorphisms in the multidrug resistance‐associated protein 4 (MRP4)
TL;DR: Six exonic regions in MRP4 encompassing the key membrane spanning domain (MSD) or the nucleotide‐binding domains (NBD) were assessed and six SNPs most likely to result in loss of transporter function were identified.
Journal ArticleDOI
Immunotherapy in Biliary Tract Cancers: Where Are We?
TL;DR: The evidence for immunotherapy use in cholangiocarcinoma is reviewed, new novel options for the management of biliary tract cancers are offered, and immuno-oncology is becoming another pillar of treatment along with traditional radiation, surgery, cytotoxic chemotherapy, and targeted therapies.
Journal ArticleDOI
Higher-Dose Sitagliptin and the Risk of Congestive Heart Failure in Older Adults with CKD
Flory T. Muanda,Flory T. Muanda,Matthew A. Weir,Matthew A. Weir,Lavanya Bathini,Lavanya Bathini,Kristin K. Clemens,Kristin K. Clemens,Vlado Perkovic,Manish Sood,Manish Sood,Eric McArthur,Jessica M. Sontrop,Richard B. Kim,Amit X. Garg,Amit X. Garg +15 more
TL;DR: The risk of death or congestive heart failure was not higher in older adults with CKD starting sitagliptin at >50 versus ≤50 mg/d and the inverse probability of treatment weighting was used on the basis of propensity scores to balance baseline characteristics.
Journal ArticleDOI
Effect of immunotherapy on the survival outcomes in tumor mutational burden-high (TMB-H) microsatellite stable (MSS) metastatic colorectal cancer (mCRC): A single-institution experience.
TL;DR: In this paper , the benefit of immunotherapy for patients with mCRC with high tumor mutational burden (TMB-H) has been widely debated, and the clinical value of applying this universal cut off to patients with MCC needs further investigation.
Journal ArticleDOI
Prospective cohort study of the impact of hospital-wide dihydropyrimidine dehydrogenase (DPYD) genotype testing for fluoropyrimidine-based chemotherapy on adverse events and hospital costs.
Theodore J. Wigle,Brandi L. Povitz,Wendy A. Teft,Robin Legan,John Lenehan,Markus Gulilat,Stephanie Nevison,Justin Kritzinger,Veera Punaganty,Denise Keller,Suhair AlShanteer,Robin Francis,Victoria Siebring,Sisira Sarma,Yun-Hee Choi,Stephen Welch,Eric Winquist,Ute I. Schwarz,Richard B. Kim +18 more
TL;DR: F fluoropyrimidines remain integral components of modern chemotherapy for solid tumors, and their toxicities can be reduced by pretreatment DPYD genotyping, and this work demonstrated this ability by reducing the toxicities of these drugs by up to 70% in patients treated with DPYD.